Earnings Per Share (EPS) of $0.02, surpassing estimates.Revenue reached $161.13 million, exceeding expectations.Financial Health indicated by a P/E ratio of approximately 22.46 and a low debt-to-equity ratio of 0.15.Trex Company, Inc. (NYSE:TREX) is a leading manufacturer of wood-alternative decking and railing products. As the largest in its industry, Trex has established a strong market presence. The company competes with other manufacturers in the building materials sector, focusing on sustainable and in ...

Financial Performance - Addus HomeCare reported a 25.6% increase in net service revenues, reaching $373.1 million for the fourth quarter of 2025 [2][6] - The company's net income for the fourth quarter was $29.8 million, or $1.61 per diluted share, with adjusted net income per diluted share increasing by 28.3% year-over-year to $1.77 [3][6] - Adjusted EBITDA grew by 33.3% year-over-year, amounting to $50.3 million, indicating strong financial health and cash flow generation [4][6] Stock Performance - Despite strong financial results, Addus HomeCare's stock price has decreased by 10.57%, currently trading at $105.20 [4][6] - The stock has fluctuated between $101 and $113 today, with a 52-week high of $124.44 and a low of $88.96 [5] - The company's market capitalization is approximately $1.94 billion, with a trading volume of 679,173 shares, reflecting strong investor interest [5]

For the quarter ended December 2025, Axsome Therapeutics (AXSM) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Appian (APPN) reported $202.87 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 21.7%. EPS of $0.15 for the same period compares to $0 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $189.1 million, representing a surprise of +7.28%. The company delivered an EPS surprise of +59.57%, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Enpro (NPO) reported $295.4 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 14.3%. EPS of $1.99 for the same period compares to $1.57 a year ago.The reported revenue represents a surprise of +5.31% over the Zacks Consensus Estimate of $280.5 million. With the consensus EPS estimate being $1.91, the EPS surprise was +4.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

ReposiTrak reported an EPS of $0.08, slightly below the estimated $0.09 but exceeded revenue expectations with $5.9 million.The company saw a 7% increase in total revenue, reaching $5.9 million up from $5.5 million the previous year.TRAK's financial health is solid with a P/E ratio of approximately 25.36, a low debt-to-equity ratio of 0.008, and a current ratio of approximately 5.45.ReposiTrak, Inc. (NYSE:TRAK) is a leading player in the food traceability and regulatory compliance sector. The company is kno ...

Core Insights - Glaukos reported revenue of $143.12 million for Q4 2025, a year-over-year increase of 35.7% and slightly above the Zacks Consensus Estimate of $142.93 million, resulting in a surprise of +0.13% [1] - The company reported an EPS of -$0.28, which is an improvement from -$0.40 a year ago, but fell short of the consensus estimate of -$0.22, leading to an EPS surprise of -26.47% [1] Revenue Performance - International Glaucoma revenues reached $32.78 million, exceeding the average estimate of $31.67 million by six analysts, representing a year-over-year increase of +17.6% [4] - United States Glaucoma revenues were reported at $86.4 million, surpassing the average estimate of $81.11 million, with a significant year-over-year change of +53.5% [4] - Net Sales for Corneal Health amounted to $24 million, exceeding the average estimate of $21.06 million, reflecting a year-over-year increase of +12.4% [4] - Net Sales for Glaucoma totaled $119.2 million, above the average estimate of $112.79 million, indicating a year-over-year change of +41.7% [4] Stock Performance - Over the past month, Glaukos shares have returned -9%, compared to a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Zillow Group reported revenue of $654 million for the quarter ended December 2025, marking an 18.1% increase year-over-year, with EPS at $0.39 compared to $0.27 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $649.76 million by 0.65%, while the EPS fell short of the consensus estimate of $0.42 by 6.25% [1] Financial Performance Metrics - Average Monthly Unique Users for Zillow's mobile applications and websites reached 221 million, surpassing the estimated 215.1 million [4] - Total visits to mobile applications and websites were 2.1 billion, slightly above the average estimate of 2.11 billion [4] - Residential revenue was reported at $418 million, exceeding the average estimate of $415.98 million, reflecting an 8% year-over-year increase [4] - Revenue from other segments was $11 million, compared to the average estimate of $11.62 million, showing a 10% year-over-year increase [4] - Mortgage revenue reached $57 million, surpassing the average estimate of $50.89 million, with a significant year-over-year increase of 39% [4] - Rental revenue was reported at $168 million, slightly below the estimated $172.17 million, but still reflecting a substantial year-over-year increase of 44.8% [4] Stock Performance - Zillow's shares have declined by 19.7% over the past month, contrasting with the Zacks S&P 500 composite, which remained unchanged [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Cognizant Technology Solutions Corporation (CTSH) is a leading provider of IT, consulting, and business process services, competing with major players like Accenture and Infosys [1] Stock Performance - Over the past month, CTSH has shown a modest gain of 0.53%, indicating steady growth and investor confidence [2] - In the last 10 days, the stock experienced a decline of 3.16%, presenting a potential buying opportunity as it has touched a local minimum, suggesting a possible rebound [2][6] Growth Potential - CTSH's growth potential is forecasted at an impressive 15.09%, driven by market trends, company performance, and industry outlook, making it attractive for investors seeking future appreciation [3] Financial Health - The company has a strong Piotroski Score of 8, indicating robust financial health and effective management, providing reassurance to investors about its stability [4][6] Analyst Target Price - Analysts have set a target price for CTSH at $94.44, reflecting significant upside potential from current levels and confidence in the company's ability to achieve growth objectives [5]

Core Insights - Woodward, Inc. is set to release its Q1 fiscal 2026 earnings on February 2, 2026, with an expected EPS of $1.63 and projected revenue of $893.2 million [1][6] Group 1: Growth Drivers - The Aerospace segment is identified as a key growth catalyst, with a forecasted revenue increase of 15.4% year-over-year, contributing to a 20.7% rise in EPS [2][6] - The company's strategic shift from its China on-highway business to focus on the Industrial segment aligns with its goal to strengthen core operations [3] Group 2: Financial Health - Woodward demonstrates strong financial stability with a low debt-to-equity ratio of approximately 0.096, indicating minimal reliance on debt financing [4] - The current ratio of about 2.08 reflects robust short-term financial health, with current assets more than double current liabilities [4] Group 3: Performance and Expectations - The company has consistently exceeded the Zacks Consensus Estimate in the last four quarters, achieving an average earnings surprise of 14.66% [5] - The upcoming earnings call is crucial for investors to assess the sustainability of growth trends and future earnings expectations [5]